Screening for prostate cancer may have limited impact on decreasing cancer-related mortality. A major disadvantage is overdiagnosis, whereby lesions are identified that would not become evident during the man’s lifetime if screening had taken place. The present study aims to estimate rate of overdiagnosis using Finnish data from European randomized trial screening. We used 80,149 men a or contr...